Phase 3Completed

Clinical Study to Evaluate PRO-169 for Diabetic Macular Edema

Phase III Non-inferiority Clinical Study to Evaluate the Efficacy and Safety of Intravitreous PRO-169 Compared to Ranibizumab for Diabetic Macular Edema

Sponsor
Laboratorios Sophia S.A de C.V. (Industry)
Enrollment
509 enrolled
Conditions
Diabetic Macular Edema
Interventions
Bevacizumab; Lucentis®
Ages
adults, older adults
Registry
NCT05217680

Full record on ClinicalTrials.gov

From the registry

Phase III clinical study to evaluate the efficacy, expressed as improvement in visual acuity in patients suffering diabetic macular edema after one year of treatment with PRO-169, compared to treatment with Lucentis® (ranibizumab).

Primary outcomes

  • Best Corrected Visual Acuity

History

  1. Last registry update

  2. Results first posted

  3. Study completion

  4. Primary completion

  5. Registered

  6. Started